Buying guide
Maestro vs CORI in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
Neither Maestro nor CORI leads across the verified dimensions on DEPLOY's record as of 2026; the comparison table holds every sourced figure side by side.
- Maestro has the lower recorded price.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Moon Surgical | Smith+Nephew |
| Form factor | surgical | surgical |
| Maturity | commercial | commercial |
| Autonomy | ◐ not independently verified | ◐ not independently verified |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | $300,000-$800,000 (analyst estimate) | $600,000-$1,200,000 (analyst estimate) |
| Capability claims |
|
|
| Brain | — | — |
| Verified deployments | 1Moon Surgical | 1Smith+Nephew |
| Privacy practices | — | — |
| Sources on file | 9 | 11 |
Track this matchup
Get told the moment Maestro or CORI changes. Verified changes only, the second they are real. No press-release noise.
Maestro
CORI
Editorial summaries
Maestro
Moon Surgical's Maestro is a laparoscopic surgical-assistant platform (it holds and positions instruments and the endoscope alongside the surgeon, not a full master-slave teleoperated replacement system) and the assistive-laparoscopy archetype of DEPLOY's surgical cluster, editorially distinct from the replacement-robotics of Intuitive, Medtronic, and CMR. Its ScoPilot software is shipped AI (NVIDIA Holoscan-powered) for intraoperative scope control.
On regulatory status (a correction worth recording): the Maestro received FDA 510(k) clearance K240598 on June 5, 2024 (not December 2023), and ScoPilot was FDA-cleared in 2025 with a Predetermined Change Control Plan. As enterprise B2B surgical equipment, there is no consumer price.
CORI
Smith+Nephew's CORI Surgical System is a compact, surgeon-controlled handheld robotics platform for orthopedic knee surgery and the handheld, imageless archetype of the orthopedic sub-cohort. It is imageless (no pre-operative CT or MRI): the surgeon paints the joint surface intra-operatively to build a 3D bone model, then uses a handheld robotic bur whose cutting speed and exposure are robotically controlled to the surgical plan, with optical navigation.
Its small footprint positions it for ambulatory surgery centers and outpatient ORs. It is AI-augmented but surgeon-controlled, not autonomous. A critical verified-vs-claimed distinction aggregators routinely blur: CORI's robotic burring is cleared for the knee only (total, partial/unicompartmental, and revision knee); its hip capability is navigation-only (RI.HIP NAVIGATION, cleared January 2022), not robotic burring.
Made by Smith+Nephew (LSE: SN; NYSE: SNN). As enterprise B2B surgical equipment, there is no consumer price.
Common questions
How do Maestro and CORI differ?
What is the difference between Maestro and CORI?
Which is cheaper, Maestro or CORI?
Is Maestro or CORI more autonomous?
Recent coverage
- Collibra brings runtime governance to enterprise AI agentsMaestro · SiliconANGLE · 2026-09-25
- Ryuichi Sakamoto’s final memoir lays bare a maestro’s final questionsMaestro · The Japan Times · 2026-09-07
- Smith+Nephew announces first clinical cases with the next generation CORI XT Handheld Robotics Platform across knee and shoulder arthroplastyCORI · Ben Smith, Deploy Editor · 2026-06-08
- Smith+Nephew Announces New Strategy and 2028 Financial TargetsCORI · Ben Smith, Deploy Editor · 2025-12-08
Related comparisons
Keep researching
Keep reading
Ask the registry
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.